Sitemap - 2021 - The Parallax View

Q3 2021 13F Review + Composite Ticker List

$GLUE | Monte Rosa Therapeutics

$TLIS | Talis, the Dark Horse of Point-of-Care Testing?

CD47: Eating Up Cancer and Biobucks

Q2 2021 13F Review

$CCCC | C4 Therapeutics

Exclusive: $NRIX | Nurix Therapeutics

Exclusive: $KYMR | Kymera Therapeutics

Exclusive: $ARVN | Arvinas

You've Been Targeted for Termination

$INFI | Infinity Pharma's bet on PI3K-γ

From Germophobe to Germophile

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts